Buy or sell Trigemina stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Trigemina Stock

Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.

Founded

2006

Headquarters

Moraga CA, US

Total Funding

$23.1M

About Trigemina Stock

Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.

Funding History

December 2006$2.0M
December 2009$305K
October 2010$400K
April 2014$8.0M
June 2015$10.0M
July 2017$2.4M

Management

Chief Medical Officer

Shashidhar Kori

Co-Founder

Martin Angst

Co-Founder

William Frey II

Chief Medical Advisor

Stephen Silberstein

Founder, Chief Scientist

David C Yeomans

Chairman

Charles Yeomans

Chief Financial Officer & Chief Operating Officer

Michael Leonard

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Trigemina or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo